Functional expression of tumor necrosis factor-related apoptosis-inducing ligand in human colonic adenocarcinoma cells

被引:22
作者
Inoue, H [1 ]
Shiraki, K [1 ]
Yamanaka, T [1 ]
Ohmori, S [1 ]
Sakai, T [1 ]
Deguchi, M [1 ]
Okano, H [1 ]
Murata, K [1 ]
Sugimoto, K [1 ]
Nakano, T [1 ]
机构
[1] Mie Univ, Dept Internal Med 1, Sch Med, Tsu, Mie 5148507, Japan
关键词
D O I
10.1097/01.LAB.0000027838.69455.39
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 [基础医学];
摘要
TNF-related apoptosis-inclucing ligand (TRAIL) can induce apoptosis in various transformed cell lines. Therefore, we investigated TRAIL sensitivity, TRAIL-induced nuclear factor-kappaB (NF-kappaB) activation, and expression of TRAIL in human colonic adenocarcinoma cell lines (HT-29, LS180, SK-CO-1). All four TRAIL receptors (TRAIL-R1 through TRAIL-R4) are expressed in these cell lines. TRAIL sensitivity was assessed by assay of cell viability. Cancer cell viabilities were 83 +/- 3.1 % (HT-29), 90 +/- 4.3% (LS180), and 88 +/- 6.3% (SK-CO-1) at 24 hours after the addition of 100 ng/ml TRAIL, indicating that these cell lines were relatively resistant to TRAIL. Activation of NF-kappaB was variably influenced by TRAIL administration, with no consistent tendency among the cell lines, indicating that TRAIL-induced NF-kappaB activation might be cell-type dependent. In contrast, TRAIL was expressed in the human colonic adenocarcinoma cell lines by Western blotting and RT-PCR. Increased expression of TRAIL on umor cells was observed by flow cytometry after cytokine stimulation (IFN-gamma, TNF-alpha) or the addition of chemotherapeutic agents (camptothecin, doxolubicin hydrochloride). TRAIL on HT-29 cells was functional and able to induce apoptosis in Jurkat cells. Jurkat cell viability was increased by the addition of TRAILR1-R4-Fc. In the presence of various cytokines or chemotherapeutic agents, functional TRAIL is expressed on the surface of tumor cells, and this expressed TRAIL might contribute to tumor immune privilege by inducing apoptosis of activated human lymphocytes.
引用
收藏
页码:1111 / 1119
页数:9
相关论文
共 33 条
[1]
A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION [J].
BELLGRAU, D ;
GOLD, D ;
SELAWRY, H ;
MOORE, J ;
FRANZUSOFF, A ;
DUKE, RC .
NATURE, 1995, 377 (6550) :630-632
[2]
The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain [J].
Degli-Esposti, MA ;
Dougall, WC ;
Smolak, PJ ;
Waugh, JY ;
Smith, CA ;
Goodwin, RG .
IMMUNITY, 1997, 7 (06) :813-820
[3]
Fujikawa K, 2000, ANTICANCER RES, V20, P1927
[4]
Gliniak B, 1999, CANCER RES, V59, P6153
[5]
Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival [J].
Hohlbaum, AM ;
Moe, S ;
Marshak-Rothstein, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (07) :1209-1219
[6]
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity [J].
Ichikawa, K ;
Liu, WM ;
Zhao, LM ;
Wang, Z ;
Liu, D ;
Ohtsuka, T ;
Zhang, HG ;
Mountz, JD ;
Koopman, WJ ;
Kimberly, RP ;
Zhou, T .
NATURE MEDICINE, 2001, 7 (08) :954-960
[7]
Survivin promotes cell proliferation in human hepatocellular carcinoma [J].
Ito, T ;
Shiraki, K ;
Sugimoto, K ;
Yamanaka, T ;
Fujikawa, K ;
Ito, M ;
Takase, K ;
Moriyama, M ;
Kawano, H ;
Hayashida, M ;
Nakano, T ;
Suzuki, A .
HEPATOLOGY, 2000, 31 (05) :1080-1085
[8]
Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction [J].
Kang, SM ;
Schneider, DB ;
Lin, ZH ;
Hanahan, D ;
Dichek, DA ;
Stock, PG ;
Baekkeskov, S .
NATURE MEDICINE, 1997, 3 (07) :738-743
[9]
Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression [J].
Korbutt, GS ;
Elliott, JF ;
Rajotte, RV .
DIABETES, 1997, 46 (02) :317-322
[10]
Lacour S, 2001, CANCER RES, V61, P1645